

Special Issue

Immunocyto/Histochemistry in the Era of Immunotherapy

Message from the Guest Editors

Immunotherapy in oncology is a breakthrough in the treatment of cancer. Treatment of cancer with immune checkpoint inhibitors (ICI) capable of unleashing T cells to exponentially expand and kill transformed cells, is the most recent and appealing treatment strategy being developed in the last decade. ICIs have been improving the survival of cancer patients. Nevertheless, not all patients respond and some of them show severe autoimmune toxicities and only 20–30% of treated patients present long term benefits. It is compelling to validate predictive and prognostic biomarkers to identify patients who are most likely to benefit from immunotherapy upfront and those who need to integrate/combine the immune-treatment with other strategies that can synergize the otherwise useless immunotherapy treatment. While some predictive factors of response to ICIs have been proposed, including PD-L1 expression, high tumor mutational burden, and mismatch repair gene defects, reliable biomarkers for the resistance to treatment are still lacking. This is in part due to the complexity of the tumor immune microenvironment and its impact on the immune drug efficacy.

Guest Editors


Dr. Ilaria Grazia Zizzari

Dr. Ilary Ruscito

Prof. Dr. A. Rughetti

Deadline for manuscript submissions

closed (30 September 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/52589

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).